HUP0101734A2 - Frameshift mutants of betha-amyloid precursor protein and ubiquitin-b and their use - Google Patents

Frameshift mutants of betha-amyloid precursor protein and ubiquitin-b and their use

Info

Publication number
HUP0101734A2
HUP0101734A2 HU0101734A HUP0101734A HUP0101734A2 HU P0101734 A2 HUP0101734 A2 HU P0101734A2 HU 0101734 A HU0101734 A HU 0101734A HU P0101734 A HUP0101734 A HU P0101734A HU P0101734 A2 HUP0101734 A2 HU P0101734A2
Authority
HU
Hungary
Prior art keywords
disease
alzheimer
betha
ubiquitin
precursor protein
Prior art date
Application number
HU0101734A
Other languages
Hungarian (hu)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Mona Moller
Original Assignee
Norsk Hydro Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro Asa filed Critical Norsk Hydro Asa
Publication of HUP0101734A2 publication Critical patent/HUP0101734A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya Alzheimer-kór vagy Down-kór kezelésére alkalmaspeptid, amely Alzheimer-kórral vagy Down-kórral összefüggőkereteltolódásos mutáció eredményeként keletkezett mutáns <APP vagyUbi-B protein fragmense, és vagy teljes hosszúságú vagyantigénbemutató sejt által végzett feldolgozását követően elnyertalakjában T-sejtes válaszreakció kiváltására képes, továbbá akereteltolódásos mutáns peptidet kódoló DNS-szekvencia és az azttartalmazó vektor. A találmány tárgyát képezik továbbá a peptideket vagy a DNS-szekvenciákat tartalmazó gyógyászati készítmények és vakcinák. Atalálmány tárgya továbbá eljárás Alzheimer-kórban szenvedő vagy arrahajlamos, vagy Down-kórban szenvedő páciens kezelésére. ÓThe subject of the invention is a peptide suitable for the treatment of Alzheimer's disease or Down's disease, which is a fragment of a mutant <APP or Ubi-B protein produced as a result of a frameshift mutation associated with Alzheimer's disease or Down's disease, and either full-length or in its form obtained after processing by an antigen-presenting cell to trigger a T-cell response able, and the DNA sequence encoding the mutant peptide and the vector containing it. The invention also relates to pharmaceutical preparations and vaccines containing peptides or DNA sequences. The subject of the invention is also a method for the treatment of a patient suffering from Alzheimer's disease or prone to it, or suffering from Down's disease. HE

HU0101734A 1998-05-08 1999-04-30 Frameshift mutants of betha-amyloid precursor protein and ubiquitin-b and their use HUP0101734A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19982098A NO314086B1 (en) 1998-05-08 1998-05-08 Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
PCT/NO1999/000141 WO1999058564A1 (en) 1998-05-08 1999-04-30 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use

Publications (1)

Publication Number Publication Date
HUP0101734A2 true HUP0101734A2 (en) 2001-09-28

Family

ID=19902022

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101734A HUP0101734A2 (en) 1998-05-08 1999-04-30 Frameshift mutants of betha-amyloid precursor protein and ubiquitin-b and their use

Country Status (11)

Country Link
US (1) US6861057B2 (en)
EP (1) EP1075490A1 (en)
JP (1) JP2002514658A (en)
CN (1) CN1300294A (en)
AR (1) AR018603A1 (en)
AU (1) AU755736B2 (en)
CA (1) CA2327523A1 (en)
HU (1) HUP0101734A2 (en)
NO (1) NO314086B1 (en)
PL (1) PL344186A1 (en)
WO (1) WO1999058564A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (en) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
NO315238B1 (en) 1998-05-08 2003-08-04 Gemvax As Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2388559A1 (en) * 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CN100447153C (en) * 2000-04-11 2008-12-31 首都医科大学宣武医院 Novel 11 peptide, preparation method and application thereof
US7034000B2 (en) * 2000-10-27 2006-04-25 The Brigham And Women's Hospital, Inc. Peptides derived from the human amyloid precursor protein
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7622446B2 (en) 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
EP2316849A2 (en) * 2001-04-18 2011-05-04 The Open University Polypeptides comprising RER, derivatives and uses thereof
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR101241272B1 (en) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Yeast-based vaccines as immunotherapy
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
EP1814917A2 (en) * 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
CN101432302A (en) 2005-11-30 2009-05-13 艾博特公司 Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibod
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
AT506820B1 (en) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh VZZINE AGAINST ALZHEIMER DISEASE
JP2012503011A (en) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド Immunotherapy of chronic hepatitis C virus infection
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2018213766A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for improving cognition
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB9410922D0 (en) 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
JP2001522241A (en) 1997-04-10 2001-11-13 ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ Diagnostic methods and reagents
NO315238B1 (en) 1998-05-08 2003-08-04 Gemvax As Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid
AU2715601A (en) * 1999-12-03 2001-06-12 Koninklijke Nederlandse Akademie Van Wetenschappen Clearance of aberrant protein in correlation with disease
EP1237930B1 (en) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides

Also Published As

Publication number Publication date
AU755736B2 (en) 2002-12-19
JP2002514658A (en) 2002-05-21
AU5451599A (en) 1999-11-29
CN1300294A (en) 2001-06-20
NO982098D0 (en) 1998-05-08
US20030171266A1 (en) 2003-09-11
WO1999058564A1 (en) 1999-11-18
EP1075490A1 (en) 2001-02-14
NO982098L (en) 1999-11-09
AR018603A1 (en) 2001-11-28
US6861057B2 (en) 2005-03-01
WO1999058564B1 (en) 2000-01-27
PL344186A1 (en) 2001-10-08
NO314086B1 (en) 2003-01-27
CA2327523A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
HUP0101734A2 (en) Frameshift mutants of betha-amyloid precursor protein and ubiquitin-b and their use
HUP0101432A2 (en) Peptides that ellicit, cellular immunity
HUP0300814A2 (en) Peptide selection method
HUP0203409A2 (en) Interferon gamma conjugates
HUP0400669A2 (en) Novel method for down-regulation of amyloid
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
JP2002534959A (en) Methods for modifying immunogenic proteins
AU6576800A (en) Use of a polypeptide for detecting, preventing or treating pathological condition associated with a degenerative, neurological or autoimmune disease
HUP0302965A2 (en) Vaccine
NZ551802A (en) A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
HUP0303753A2 (en) Reducing the immunogenicity of fusion proteins
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
JP2009108097A (en) Peptide with increased binding affinity for hla molecule
NO20070618L (en) Compounds and Methods for Immunotherapy and Diagnosis of Tuberculosis.
HUP0102479A2 (en) Basbo29 polynucleotides(s) and polypeptides from neisseria meningitidis
WO1997048370A3 (en) Vaccines comprising synthetic genes
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
JPH08502244A (en) Immunomodulatory peptide
DK1025236T3 (en) Human checkpoint kinase, HCDS1, preparations and methods
GB9219936D0 (en) Vaccines
HUP0302481A2 (en) Virulence genes, proteins, and their use
NO960858L (en) Uses of myelin - oligodendrocyte glycoprotein and peptide portions thereof in autoimmune disease methods
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
HUP0402071A2 (en) Modified leptin with reduced immunogenicity
JPH10505665A (en) Identification and production of antigenic peptides and their use as vaccines